ClinASO: An open-source platform for rapid drug discovery of gapmer antisense oligonucleotides

Gapmer antisense oligonucleotides (ASOs) enable sequence-specific degradation of target mRNAs, offering therapeutic access to previously “undruggable” genes and holding great promise for treating chronic and genetic diseases. However, the rapid development of ASO therapeutics remains limited by chal...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shunkai Chen, Hao Liu, Dezi Cong, Ao Dong, Yuhang Wang, Jingyi Bi, Shijie Guo, Juan Yang, Xiaolei Wang, Guiping Ren, Ke Zhang, Haisheng Wang, Fan Lai, Yunkun Dang
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-06-01
Col·lecció:	Molecular Therapy: Nucleic Acids
Matèries:	MT: oligonucleotides: therapies and applications MT: Therapies and Applications gapmer antisense oligonucleotides RNA therapeutics sequence design metabolic dysfunction-associated
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2162253126001046
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!